میسێنمادینۆن ئاستەیت

میسێنمادینۆن ئاستەیت (MMA)، ھەروەھا وەک (methylenedehydroacetoxyprogesterone میسیلێن-دیھایدرۆسیتۆکسی-پرۆجێسترۆن)ـش ناسراوە (MDAP) و لەژێر ناوە بازرگانییەکانی (سوپەرلوتین) و (ئەنتیجێست) دەفرۆشرێت، دەرمانێکی پرۆجستینە کە گەشەی پێدانی لە چێکۆسلۆڤاکیا بۆ کراوە لە ١٩٦٠ـەکان^[١]^[٢]^[٣]^[٤]^[٥]^[٦]^[٧]^[٨]^[٩]^[١٠]^[١١]^[١٢]^[١٣] لە ڕێگەی دەمەوە بەکاردێت^[١]

سەرچاوەکان[دەستکاری]

دەروازەی زانست

^ ^ئ ^ا G.W.A Milne (1 November 2017). Ashgate Handbook of Endocrine Agents and Steroids. Taylor & Francis. pp. 158–. ISBN 978-1-351-74347-1.
^ J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 93, 318. ISBN 978-94-009-8195-9.
^ Cynthia A Challener (23 October 2017). Chiral Drugs. Taylor & Francis. pp. 1127–. ISBN 978-1-351-80804-0.
^ Horský, Jan; Presl, Jiří (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". Ovarian Function and its Disorders. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN 978-94-009-8197-3.
^ J.P. Lavery; J.S. Sanfilippo (6 December 2012). Pediatric and Adolescent Obstetrics and Gynecology. Springer Science & Business Media. pp. 236–. ISBN 978-1-4612-5064-7.
^ R. G. Denkewalter; M. Tishler; G. Ehrhart; J. H. Biel, B. K. B. Lum, J. Büchi, C. A. Winter, K. Münzel, W. Kunz, E. J. Ariëns, F. Labhardt (8 March 2013). Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 407–. ISBN 978-3-0348-7059-7.{{cite book}}: CS1 maint: multiple names: پێرستی نووسەران (link)
^ HONTELA S (September 1964). "[Clinical experience with the new peroral gestagen, 16-methylene-6-dehydro-17-alpha-acetoxyprogesterone (MDAP)]". Zentralbl Gynakol (بە ئەڵمانی). 86: 1327–32. PMID 14324038.
^ Králová A, Stĕrba R, Valová B (June 1965). "[Superlutin--a new Czechoslovak oral gestagen]". Cesk Gynekol (بە چیکی). 30 (5): 351–5. PMID 5835891.
^ Dvorák K, Presl J (November 1986). "[Biological testing of methenmadinone acetate (Superlutin Spofa) in clinical trials]". Cesk Gynekol (بە چیکی). 51 (9): 714–9. PMID 3539369.
^ Drázdil M (December 1966). "[Superlutin]". Cesk Farm (بە چیکی). 15 (10): 543–4. PMID 5980773.
^ Horák C, Sedliak M (February 1966). "[Our experience in the treatment of menstruation disorders with Superlutin]". Cesk Gynekol (بە سلۆڤاكی). 31 (1): 86–8. PMID 5932092.
^ Stĕrba R (July 1967). "[3-Methylether-ethinylestradiol (Mestranol) and 6-dehydro-16-methylene-17-alpha-acetoxyprogesterone (Superlutin) in the therapy of functional bleedings]". Zentralbl Gynakol (بە ئەڵمانی). 89 (28): 1030–1. PMID 5586402.
^ Sterba, R. (1969). Several experiences with injected progesterones. Ceskoslovenska Gynekologie, 34(7), 407-409. https://www.popline.org/node/506944 ١٦ی ئەیلوولی ٢٠١٨ لە وەیبەک مەشین، ئەرشیڤ کراوە.

[Milne2017-1] ئ ^ا G.W.A Milne (1 November 2017). Ashgate Handbook of Endocrine Agents and Steroids. Taylor & Francis. pp. 158–. ISBN 978-1-351-74347-1.

[HorskyPresl2012-2] J. Horsky; J. Presl (6 December 2012). Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 93, 318. ISBN 978-94-009-8195-9.

[Challener2017-3] Cynthia A Challener (23 October 2017). Chiral Drugs. Taylor & Francis. pp. 1127–. ISBN 978-1-351-80804-0.

[HorskýPresl1981-4] Horský, Jan; Presl, Jiří (1981). "Hormonal Treatment of Disorders of the Menstrual Cycle". Ovarian Function and its Disorders. pp. 309–332. doi:10.1007/978-94-009-8195-9_11. ISBN 978-94-009-8197-3.

[LaverySanfilippo2012-5] J.P. Lavery; J.S. Sanfilippo (6 December 2012). Pediatric and Adolescent Obstetrics and Gynecology. Springer Science & Business Media. pp. 236–. ISBN 978-1-4612-5064-7.

[DenkewalterTishler2013-6] R. G. Denkewalter; M. Tishler; G. Ehrhart; J. H. Biel, B. K. B. Lum, J. Büchi, C. A. Winter, K. Münzel, W. Kunz, E. J. Ariëns, F. Labhardt (8 March 2013). Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques. Birkhäuser. pp. 407–. ISBN 978-3-0348-7059-7.{{cite book}}: CS1 maint: multiple names: پێرستی نووسەران (link)

[pmid_14324038-7] HONTELA S (September 1964). "[Clinical experience with the new peroral gestagen, 16-methylene-6-dehydro-17-alpha-acetoxyprogesterone (MDAP)]". Zentralbl Gynakol (بە ئەڵمانی). 86: 1327–32. PMID 14324038.

[pmid_5835891-8] Králová A, Stĕrba R, Valová B (June 1965). "[Superlutin--a new Czechoslovak oral gestagen]". Cesk Gynekol (بە چیکی). 30 (5): 351–5. PMID 5835891.

[pmid_3539369-9] Dvorák K, Presl J (November 1986). "[Biological testing of methenmadinone acetate (Superlutin Spofa) in clinical trials]". Cesk Gynekol (بە چیکی). 51 (9): 714–9. PMID 3539369.

[pmid_5980773-10] Drázdil M (December 1966). "[Superlutin]". Cesk Farm (بە چیکی). 15 (10): 543–4. PMID 5980773.

[pmid_59320922-11] Horák C, Sedliak M (February 1966). "[Our experience in the treatment of menstruation disorders with Superlutin]". Cesk Gynekol (بە سلۆڤاكی). 31 (1): 86–8. PMID 5932092.

[pmid_55864022-12] Stĕrba R (July 1967). "[3-Methylether-ethinylestradiol (Mestranol) and 6-dehydro-16-methylene-17-alpha-acetoxyprogesterone (Superlutin) in the therapy of functional bleedings]". Zentralbl Gynakol (بە ئەڵمانی). 89 (28): 1030–1. PMID 5586402.

[Sterba19692-13] Sterba, R. (1969). Several experiences with injected progesterones. Ceskoslovenska Gynekologie, 34(7), 407-409. https://www.popline.org/node/506944 ١٦ی ئەیلوولی ٢٠١٨ لە وەیبەک مەشین، ئەرشیڤ کراوە.

[١]

[٢]

[٣]

[٤]

[٥]

[٦]

[٧]

[٨]

[٩]

[١٠]

[١١]

[١٢]

[١٣]